The impact of migraine on quality of life and work-related activity is substantial but underestimated. However, migraine burden is difficult to assess both quantitatively and qualitatively due to the transient nature of migraine headaches and patient-reporting inconsistencies. The fact that headache disorders account for over 60% of neurological conditions and, according to recent analysis using disease-specific measures, reported in the Global Burden of Disease study, disability-adjusted life years (DALYs) run into the millions, suggests that there is a significant gap between knowledge and practice.
This new expert-led curriculum-based program covers the latest advances in migraine classification and acute management and will help you translate this knowledge into your clinical practice and improve your patients’ outcomes. The content will be published in phases, following a predetermined curriculum of learning activities which develop from the first stage, knowledge, moving onto competence and finally ending with performance.
Would you like to know more?
Learners will be able to:
- Utilize the latest pathophysiological advances to improve the identification and classification of migraine
- Debate and adopt appropriately tailored acute migraine treatment to the individual patient to optimize safety, efficacy, and adherence
- Evaluate the latest data on novel acute treatments and discuss where their use may be incorporated into current clinical practice
- Interpret the success of acute migraine treatment using up-to-date clinical endpoints
Uwe Reuter, Program Director
Professor of Neurology, Charité University Hospital, Berlin, Germany
Prof Dr Uwe Reuter is a neurologist and partner in the headache program at Charité Universitätsmedizin Berlin, Germany. Upon completing his residency training in Berlin he attended Harvard Medical School as a postdoctoral fellow. During his time in Boston he focused on basic research in primary headaches and migraine aura, and published several peer-reviewed publications in high impact journals. Uwe Reuter has been the principal investigator in numerous clinical trials and projects. He has published multiple manuscripts on CGRP and is the lead author in the first placebo controlled clinical trial with a monoclonal CGRP antibody for migraine prevention in patients, who previously did not respond to 2-4 conventional oral migraine preventatives.
He is a member of several national and international headache organizations and currently serves as a board member of the European Headache Federation.
Uwe Reuter discloses financial support and/or sponsorship from Allergan, Amgen, Novartis, Eli Lilly, TEVA, Medscape, and StreamedUp.
Professor, Psychiatry Institute, Sao Paulo University, Sao Paulo, Brazil
Mario Peres is a neurologist, who for the past 20 years has been dedicated to headache research, clinical practice, academic training and public awareness. He is currently President of ABRACES, a Brazilian headache advocacy association, Secretary of the Brazilian Headache Society, member of the Board of Trustees of the International Headache Society, and Professor at the Psychiatry Institute, University of Sao Paulo, Brazil.
Mario Peres discloses financial support/sponsorship from Lilly, Allergan, and Novartis in speaker fees, and consultation fees from Eurofarma, Lilly, Sanofi. Peres holds patent # BR2020170233532, from INPI – Instituto Nacional da Propriedade Industrial. Registered on 30/10/2017.
Nada Hindiyeh is a board certified Neurologist and headache specialist and is currently a Clinical Assistant Professor in the department of Neurology at Stanford University. She is the Director of Clinical Research for the Stanford division of Headache Medicine and serves as principal investigator for several clinical trials.
Dr Hindiyeh was awarded the 2013 Clinical Research Fellowship in Neurotoxins by the American Academy of Neurology and under this scholarship is currently investigating a diagnostic screening protocol for chronic migraine. Other research interests include pathophysiology and novel treatments for migraine, the use of transcranial magnetic stimulation in headache disorders, and participation in clinical trials for new headache therapeutics. She is currently a member of the American Headache Society (AHS), serves on the AHS Electronic Media committee and was chosen as an AHS Emerging Leader in the field in 2017. She is also a member of the International Headache Society.
Dr Hindiyeh completed her medical degree at the University of Toledo College of Medicine in Toledo Ohio. Both her internship and neurology residency were completed at the University of California, Irvine, Medical Center, where she was chief resident. She completed her fellowship in headache and facial pain at Stanford University School of Medicine.
Nada Hindiyeh has received consultation fees from Eli Lilly and Lundbedk.
Attending Neurologist and Professor, Department of Medical Research and Department of Neurology, Taipei Veterans General Hospital, Taipei, TAIWAN
Shih-Pin Chen is a physician scientist who graduated from Faculty of Medicine and Institute of Clinical Medicine, National Yang-Ming University, Taiwan. He received his neurology resident training at Department of Neurology, Taipei Veterans General Hospital and post-doctoral fellowship training at Neurovascular Research Lab, Massachusetts General Hospital, Harvard Medical School.
Dr Chen is currently an attending physician of Department of Medical Research, Taipei Veterans General Hospital and Professor of Institute of Clinical Medicine, National Yang-Ming University. He has served as the Associate Editor of Cephalalgia (the official journal of International Headache Society) and Cephalalgia Reports since 2020. Dr Chen’s research interests focus on deciphering the pathophysiology of headache disorders, specifically, the clinical, neuroimaging, and molecular biological studies of reversible cerebral vasoconstriction syndrome (RCVS) as well as the animal models (especially cortical spreading depression) and genomics studies of migraine.
Shih-Pin Chen discloses speaker honorarium from Eli Lilly & Company.
This activity is supported by an educational grant from Lilly.
Through a variety of engaging learning techniques and content, the story of migraine will unfold as learners will discover more about the pathophysiology and how better patient communication and accurate diagnosis will lead to best-practice management and treatment and help translate knowledge into practice.
- Identify and classify migraine
- Instructive video describing the pathophysiology of the disorder and elearning activity
- Use the appropriate management approach and measure treatment success
- Individual patient profiles and e-learning activity
- Key barriers and how to overcome them and translate knowledge into practice
- Video stream of panel discussion
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.
The program will be certified with AMA PRA Category 1 Credits™; the amount of credits will be finalized as the activities are launched. Participants should claim only credit commensurate with the extent of their participation in the activities.
The following activities will be accredited:
- Phase 3: Four case studies
- Phase 3: eLearning module on measuring treatment success
- Phase 4: 1-hour video webcast
NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
In addition to the speaker faculty, NACCME and Springer Healthcare IME planners and staff include Chris Bolwell, Jules Morgan, and Rebecca Cox. Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service. Jules Morgan and Rebecca Cox have no financial relationships to disclose.